29th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Welcome and Introductions

CAR T Cells in Acute and Chronic Leukemias

Bispecific Antibodies in Lymphomas: Sequencing and Future Applications

Incorporation of Bispecific Antibodies in MM

Keynote: Future of Cell-Engaging Therapy–Next Steps to Augment Treatment

Treatment of Patients With Newly Diagnosed DLBCL

How to Sequence Treatment in Relapsed/Refractory DLBCL

Science and Biology Behind How to Optimally Sequence CAR Ts, Bispecific Antibodies, and Antibody-Drug Conjugates

Current and Emerging Paradigms in Ph-Positive Acute Lymphocytic Leukemia (ALL)

Incorporating New Strategies for Ph-Negative ALL

BCL2 Inhibition in AML and Managing the Mechanisms of Resistance

The Expanding Array of Targeted Therapy in Acute Myeloid Leukemia (AML)

First-Line Treatment of CLL (Including Investigational Approaches)

Treatment of Relapsed/Refractory CLL (Including Pipeline Agents)

New Approaches for Patients With Low-Risk MDS

What's New for Patients With High-Risk MDS

Early Therapy for High-Risk Smoldering MM: Evidence-Based Approaches

JAK2 Inhibition and Beyond in Myelofibrosis: Treatment Selection and Emerging Combinations

Management of Anemia/Thrombocytopenia in MPNs

Planning Therapy in CML: End Points and Treatment Decisions

Welcome, Introductions, and Presession Survey

New Drug Updates in Hematologic Malignancies

Multiple Myeloma: Case Study on Bispecific Antibodies

Lymphoma: Case Study on Bispecific Antibodies

Interactive Panel Discussion: Addressing Practical Issues With Integrating Cellular Therapies and Bispecific Antibodies in the Treatment Continuum